Bruker Enables Advanced Life-Science and Green-Tech Research in the UK
10 Julho 2023 - 8:00AM
Business Wire
GHz-Class NMR, Structural Biology assisted
by Artificial Intelligence, a New Scientific Software Division and
Innovative Helium Solutions at EUROMAR 2023
At the EUROMAR Conference 2023 in Scotland, Bruker showcases the
latest innovations in magnetic resonance technology for life
science and materials science research. Bruker’s contributions to
science in the United Kingdom (UK) will be further strengthened by
recent orders for two 1.2 GHz Avance™ nuclear magnetic
resonance (NMR) spectrometers from the University of Warwick and
the University of Birmingham. This major science infrastructure
investment will enable groundbreaking research into materials
properties for energy storage and biofuels, as well as structures
and interactions of proteins, nucleic acids, carbohydrates, lipids,
and metabolites in cell and pathobiology research, and drug
discovery.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230710824407/en/
SciY Product Platform for Vendor-Agnostic
Software (Graphic: Business Wire)
Both the University of Warwick and the University of Birmingham
already utilize Bruker 1.0 GHz NMR spectrometers, and the
additional 1.2 GHz Avance™ systems will propel this core UK NMR
research infrastructure to new capabilities, with unparalleled
sensitivity and resolution, empowering scientists to dive deeper
into the intricacies of materials and biomolecular systems.
Bruker also showcases the new Ascend Evo 400 MHz NMR
magnet that sets new standards for operational convenience and cost
of ownership with improved liquid helium hold-time of one year,
reducing the frequency for helium refills and streamlining
laboratory operations. This novel magnet also has further improved
field homogeneity, with new cryogenic shimming technology
originally developed for ultra-high field magnets, in order to make
sample shimming and operation even easier.
Bruker is committed to providing solutions for reducing helium
consumption, such as the new HelioSmart-R system for
collecting helium gas boil-off from magnets. The HelioSmart-R
recovery solution has now been successfully installed in
pharmaceutical labs (Merck in Darmstadt, Germany) and academic labs
(University of South Carolina, US) and Bruker anticipates numerous
additional installations throughout 2023. The new
HelioSmart-L solution for liquefaction collects and
liquifies helium boil-off from NMR magnets with over 95% recovery
rate. HelioSmart-L collects steady-state helium boil-off during
operations and during refills, and then purifies and liquefies the
helium - creating a closed loop for improved sustainability.
Bruker advances its collaboration with the Swiss Federal
Institute of Technology Zürich (ETHZ) on accelerating protein
structure determination by AI. At the heart of the collaboration is
NMRtist, a cloud computing service that uses deep
learning-based approaches to fully automate analysis of protein NMR
spectra.
Professor Roland Riek of ETHZ, Head of the Bio-NMR group in the
Department of Chemistry and Applied Biosciences, commented:
“Protein structure determination by NMR is a very time-consuming
process and requires extensive manual intervention. Our goal was to
leverage deep learning and AI to make it faster and more automated,
while still achieving accurate results.”
The results obtained by the NMRtist cloud-based platform, such
as resonance assignments, will be seamlessly integrated into more
complex workflows in the future, addressing a variety of research
questions. This collaboration between Bruker and ETHZ marks an
important step in advancing protein structure determination. With
AI-driven automation at its core, this partnership will continue to
provide researchers with faster access to accurate results for many
classes of proteins, while saving both time and expense in the
process.
Bruker has recently introduced the SciY™ platform,
which offers advanced and versatile software solutions for data
analysis and management, research lab and bioproduction QC
digitalization, as well as for scientific workflow automation. By
integrating high-performance lab software solutions, the SciY
platform provides a broad suite of vendor-agnostic software and
automation solutions for the digital transformation of the life
science and biopharma industries. The launch of SciY is led by
Bruker's Integrated Data Solutions division in collaboration with
software and biopharma automation companies Mestrelab Research,
Arxspan, Optimal Industrial Technologies, ZONTAL, and Optimal
Industrial Automation. With innovative, modular software solutions,
the SciY platform simplifies data acquisition and interpretation,
maximizing the value of data in biopharma research, development and
manufacturing.
Dr. Falko Busse, President of the Bruker BioSpin Group,
concluded: “We are pleased to support the advancements in
scientific and drug discovery research in the United Kingdom with
Bruker innovations. We view the UK investments in advanced life and
materials science research infrastructure as pivotal for the
advancement of science, drug discovery and a green-tech economy,
and we are proud to support these visionary endeavors. Our latest
advancements in magnetic resonance instrumentation and software,
now enhanced by artificial intelligence will provide our customers
with greater capabilities and productivity for scientific
research.”
To learn about Bruker at EUROMAR:
https://www.bruker.com/en/news-and-events/events/euromar.html
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230710824407/en/
Investor: Justin Ward Sr. Director, Investor Relations
& Corporate Development Bruker Corporation T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media: Markus Ziegler Sr. Director and Head of Group
Marketing Bruker BioSpin T: +49 172 3733531 E: pr@bruker.com
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024